Navigation Links
National Council on Disability Bulletin, January 2008
Date:2/15/2008

's Depression/Awareness, Recognition and Treatment (D/ART) program has earned numerous national awards, including recognition as the National Mental Health Association's most effective state executive director. Ms. Wainscott has served as a member of the Center for Mental Health Services National Advisory Council and is a founding member of the board of directors of the Campaign for Mental Health Reform.

Youth Advisory Committee Seeks Input on Aversives/Restraints and Healthcare

NCD's Youth Advisory Committee (YAC) needs your help. The YAC is gathering information as background for two different papers to support recommendations the YAC will make from a youth perspective. The role of the YAC is to provide recommendations directly to NCD regarding policy and issues affecting the lives of youth with disabilities nationwide. One topic is about the use of aversives and restraint. The other topic is about access to healthcare. For details about how you can have an opportunity to share your perspectives, please contact NCD's designated federal official for YAC, Dr. Gerrie Hawkins at ghawkins@ncd.gov. Thank you.

Quarterly Meetings

NCD's spring quarterly meeting will be held April 21-23, 2008, at the Westin Arlington Gateway, 801 North Glebe Road, Arlington, VA.

Preparations are also underway for NCD's summer and fall quarterly meetings, which will be held, respectively, July 14-16, 2008, in Seattle, WA, and October 6-8, 2008, in Kansas City, MO.

These meetings are open to the public. People with disabilities are encouraged to attend and participate in the daily public comment segments of the meetings. The agendas will be posted at http://www.ncd.gov prior to each meeting.


'/>"/>
SOURCE National Council on Disability
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. International study strengthens case for daily calcium pill
2. Yakima Health Care Leader Tapped for Leadership Post at National Association
3. Virginia Tech Report Has National Importance
4. Donate Life America Dispels Myths About Organ & Tissue Donation Among Hispanics During National Hispanic Heritage Month
5. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. National Association of Subrogation Professionals (NASP), the Largest Insurance Subrogation Association in the World - Announced Today that Leslie Wiernik has Joined the Organization as Director of Education
8. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, to Address National Drug Crisis, Keynote Grand Opening of New Allenwood, PA National Model Detox Center
9. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
10. LCA Hails International Investigators Studying Lung Cancer
11. National Patient Safety Foundation Partners with Vocera Communications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...h wraps up successful disaster relief campaign , ... -- The American Red Cross is asking people across...0 million in 30 days. This holiday season push wil... the Red Cross Campaign for Disaster Relief. Alrea...ce its launch in September, and the Red Cross hope...
(Date:12/1/2008)...Dec. 1 Medication therapy manageme...complished professionals to its,advisory board. ,...include Martin Makary, M.D.;,Michael Burcham; and...of,advisors that has helped PharmMD launch and ho...medication error, misuse, overuse and abuse. MTM ...
(Date:12/1/2008)...ec. 1 The United States...s new right hand on Saturday, November 29, as Dr. ...n, changed the bandages. , , "Wow, it looks...rom his room at Jewish Hospital. "It,s awesome," ... , Hondusky, a New York resident, went on to s...
(Date:12/1/2008)...e implant makes it more difficult to treat the mal.... 1 (HealthDay News) -- Women who have had their b...osed with early-stage breast cancer may be treated...tment known as brachytherapy, according to an Ariz...allenge to take care of these augmented women," sa...
Breaking Medicine News(10 mins):Health News:Red Cross Asks America to Help Raise $30 Million in 30 Days 2Health News:Red Cross Asks America to Help Raise $30 Million in 30 Days 3Health News:PharmMD Expands Advisory Board 2Health News:Fifth U.S. Hand Transplant Patient Gets Look at New Hand 2Health News:Radioactive 'Seed' Rx Helps Women With Implants Fight Breast Cancer 2Health News:Radioactive 'Seed' Rx Helps Women With Implants Fight Breast Cancer 3
...esearchers at the Stanford University School of Me...he researchers found that children with post-traum... hormone cortisol were likely to experience a decr...re important in memory processing and emotion. ...
...one of the reasons why Down syndrome births are hi...cording to senior Queensland health analysts. Mic...imothy Roselli and Heidi Carroll, of Queensland He...th Down syndrome in Queensland to see whether the ...
...an eat excessive amounts of food and not gain weig...more likely to develop obesity and this most commo...sed two strains of mice with differing tendencies ... diet, identified genetic and cellular mechanisms ...
...national waiting list for kidney transplants have ... matter how long they are on the list. Due to prio...these patients have developed antibodies that make...donor organs. Researchers at Emory University hav...
Other Medicine News:Health News:Severe PTSD Damages Children's Brains: Study 2Health News:Severe PTSD Damages Children's Brains: Study 3Health News:Down Syndrome Testing for All Mums? 2Health News:Study Finds Fat Type That can Protect Against Weight Gain and Diabetes 2Health News:Study Finds Fat Type That can Protect Against Weight Gain and Diabetes 3Health News:Research Improves Kidney Transplant Chances for Sensitized Patients 2Health News:Research Improves Kidney Transplant Chances for Sensitized Patients 3
(Date:11/28/2008)..., Nov. 28 Eli Lilly and ...ntal New Drug Application (sNDA) from,the U.S. Fo...duloxetine HCl),for the management of chronic pai... first half of 2009, adding data from a recently c... pain of the knee. , The decision does not ...
(Date:11/25/2008)...eness can improve recovery , , Audio and We...lable on the Mayo Clinic News Blog. Please see the... ROCHESTER, Minn., Nov. 25 /PRNewswire-USNewswir...ke patients don,t think they,re having a stroke --...their condition worsens. The findings appear in th...
(Date:11/25/2008)...alif., Nov. 25 Pharmacyc... the company has completed a Phase 1,clinical tri...lass,small-molecule Factor VIIa inhibitor. The tr...ers to evaluate the safety and pharmacologic effec...483 resulted in a linear dose,response in the Int...
(Date:11/24/2008)...N.J., Nov. 24 Leaders of...provided an update for investors on the company,s ...ive portfolio that includes 46 new entities in cli...preclinical studies. , , "Research and deve...-Plough as we continue our transformation," said F...
Breaking Medicine Technology:Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Lettuce leafy greens and E coli 370 1Lettuce leafy greens and E coli 370 2Two studies published in the Lancet 366 1Two studies published in the Lancet 366 2New Study Findings Confirm CLEXANE 28R 29 LOVENOX 28R 29 Long Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 310 1New Study Findings Confirm CLEXANE 28R 29 LOVENOX 28R 29 Long Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 310 2New Study Findings Confirm CLEXANE 28R 29 LOVENOX 28R 29 Long Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 310 3New Study Findings Confirm CLEXANE 28R 29 LOVENOX 28R 29 Long Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 310 4New Study Findings Confirm CLEXANE 28R 29 LOVENOX 28R 29 Long Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 310 5Report recommends off site disposal of secondary waste 307 1Report recommends off site disposal of secondary waste 307 2Report recommends off site disposal of secondary waste 307 3Report recommends off site disposal of secondary waste 307 4
...WSWIRE) -- New data,presented at ECCMID highlight ...f Basilea,s (SWX:BSLN) two late-stage,drug candida...ed,both for ceftobiprole, the first anti-MRSA broa..., and for isavuconazole, a,novel azole for the tre...her data on their respective breadths of spectrum,...
...- Novagali Pharma, an,emerging ophthalmic pharmace...nces today positive results from the Phase III,cli...om Vernal,Keratoconjunctivitis (VKC). In this orph...gns of disease improved in patients,receiving Veka...),was excellent. , VKC is a severe form of chronic...
Other Medicine Technology:Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 2Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 3Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 4Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 5Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 6Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 7Novagali Pharma Announces Positive Vekacia Clinical Results From,Pivotal Phase III Trial in Vernal Keratoconjunctivitis 2
...2.8mm instrument channel for superb versatility in...ion of a wide variety of accessories including tho...is model features excellent optics with a wide fie... also provides improved operability, increased BAL...
...ofiberscopes with electrosurgical capability, has ...nd for expanded bronchoscopic diagnostic and treat...l section and ergonomic design to facilitate incre...eld of view, a smaller insertion tube and distal e...
Facilitates one-lung ventilation when using dual lumen endobronchial tubes.
Double lumen tubes for selective one-lung ventilation., ,Each SHER-I-BRONCH Endobronchial Tube is packaged with pre-loaded stylet, tube-to-circuit adaptors, suction catheters and Accessories Pack (f
Medicine Products: